Search Results - "Shubham, Pant"

Metastatic Pancreatic Cancer: ASCO Guideline Update by Sohal, Davendra P.S., Kennedy, Erin B., Cinar, Pelin, Conroy, Thierry, Copur, Mehmet S., Crane, Christopher H., Garrido-Laguna, Ignacio, Lau, Michelle W., Johnson, Tyler, Krishnamurthi, Smitha, Moravek, Cassadie, O’Reilly, Eileen M., Philip, Philip A., Pant, Shubham, Shah, Manish A., Sahai, Vaibhav, Uronis, Hope E., Zaidi, Neeha, Laheru, Daniel

“…PURPOSEThe aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options…”
Get full text

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer by Bendell, Johanna C, Varghese, Anna M, Hyman, David M, Bauer, Todd M, Pant, Shubham, Callies, Sophie, Lin, Ji, Martinez, Ricardo, Wickremsinhe, Enaksha, Fink, Aaron, Wacheck, Volker, Moore, Kathleen N

“…The PI3K/mTOR pathway is frequently aberrated in cancer. LY3023414 is a potent and selective ATP-competitive inhibitor of class I PI3K isoforms, mTOR, and…”
Get full text

PARP inhibition — opportunities in pancreatic cancer by Pant, Shubham, Maitra, Anirban, Yap, Timothy A.

“…An urgent clinical need exists to improve the survival of patients with pancreatic cancer through biomarker-driven therapeutic strategies. Such approaches…”
Get full text

Pancreas Cancer‐Associated Pain Management by Coveler, Andrew L., Mizrahi, Jonathan, Eastman, Bory, Apisarnthanarax, Smith “Jim”, Dalal, Shalini, McNearney, Terry, Pant, Shubham

“…Pain is highly prevalent in patients with pancreas cancer and contributes to the morbidity of the disease. Pain may be due to pancreatic enzyme insufficiency,…”
Get full text

Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer by Perri, Giampaolo, Prakash, Laura, Wang, Huamin, Bhosale, Priya, Varadhachary, Gauri R., Wolff, Robert, Fogelman, David, Overman, Michael, Pant, Shubham, Javle, Milind, Koay, Eugene, Herman, Joseph, Kim, Michael, Ikoma, Naruhiko, Tzeng, Ching-Wei, Lee, Jeffrey E., Katz, Matthew H. G.

“…OBJECTIVE:We sought to identify potential radiologic and serologic markers of pancreatic tumor response to therapy, using pathologic major response (pMR) as…”
Get full text

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer by Voss, Martin H., Gordon, Michael S., Mita, Monica, Rini, Brian, Makker, Vicky, Macarulla, Teresa, Smith, David C., Cervantes, Andrés, Puzanov, Igor, Pili, Roberto, Wang, Ding, Jalal, Shadia, Pant, Shubham, Patel, Manish R., Neuwirth, Rachel l., Enke, Aaron, Shou, Yaping, Sedarati, Farhad, Faller, Douglas V., Burris, Howard A.

“…Background This Phase 1 dose-escalation/expansion study assessed safety/tolerability of sapanisertib, an oral, highly selective inhibitor of mTORC1/mTORC2, in…”
Get full text

Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer by Abdel-Wahab, Reham, Yap, Timothy A., Madison, Russell, Pant, Shubham, Cooke, Matthew, Wang, Kai, Zhao, Haitao, Bekaii-Saab, Tanios, Karatas, Elif, Kwong, Lawrence N., Meric-Bernstam, Funda, Borad, Mitesh, Javle, Milind

“…DNA repair gene aberrations (GAs) occur in several cancers, may be prognostic and are actionable. We investigated the frequency of DNA repair GAs in…”
Get full text

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors by Falchook, Gerald, Infante, Jeffrey, Arkenau, Hendrik-Tobias, Patel, Manish R., Dean, Emma, Borazanci, Erkut, Brenner, Andrew, Cook, Natalie, Lopez, Juanita, Pant, Shubham, Frankel, Arthur, Schmid, Peter, Moore, Kathleen, McCulloch, William, Grimmer, Katharine, O'Farrell, Marie, Kemble, George, Burris, Howard

“…We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2…”
Get full text

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences by Yao, Shuyang, Meric-Bernstam, Funda, Hong, David, Janku, Filip, Naing, Aung, Piha-Paul, Sarina Anne, Tsimberidou, Apostolia Maria, Karp, Daniel, Subbiah, Vivek, Yap, Timothy Anthony, Ahnert, Jordi Rodon, Pant, Shubham, Dumbrava, Ecaterina E Ileana, Wathoo, Chetna, Campbell, Erick, Yu, Lihou, Yamamura, Yuko, Fu, Siqing

“…Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying…”
Get full text

Clinical update on K-Ras targeted therapy in gastrointestinal cancers by Pant, Shubham, Hubbard, Joleen, Martinelli, Erika, Bekaii-Saab, Tanios

“…•KRAS-mutant pancreatic and colorectal cancer is common and difficult to target.•Direct inhibition of K-Ras has been demonstrated in preclinical…”
Get full text

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma by Noonan, Anne M, Farren, Matthew R, Geyer, Susan M, Huang, Ying, Tahiri, Sanaa, Ahn, Daniel, Mikhail, Sameh, Ciombor, Kristen K, Pant, Shubham, Aparo, Santiago, Sexton, Jennifer, Marshall, John L, Mace, Thomas A, Wu, Christina S, El-Rayes, Bassel, Timmers, Cynthia D, Zwiebel, James, Lesinski, Gregory B, Villalona-Calero, Miguel A, Bekaii-Saab, Tanios S

“…Pelareorep causes oncolysis in tumor cells with activated Ras. We hypothesized that pelareorep would have efficacy and immunomodulatory activity in metastatic…”
Get full text

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors by Azaro, Analia, Massard, Christophe, Tap, William D., Cassier, Philippe A., Merchan, Jaime, Italiano, Antoine, Anderson, Bailey, Yuen, Eunice, Yu, Danni, Oakley, Gerard, Benhadji, Karim A., Pant, Shubham

“…Summary Notch signaling plays an important role in development and tissue homeostasis. Deregulation of Notch signaling has been implicated in multiple…”
Get full text

Survival of Misdiagnosed 2,4-Dichlorophenoxyacetic Acid Poisoning Masquerading as Organophosphorus Poisoning: A Case Report by Joshi, Anjali, Joshi, Aatish, Pant, Shubham, Bhurtyal, Aakanksha, Yadav, Sunil

“…Herbicide such as 2,4-Dichlorophenoxyacetic acid is commonly used in wheat growing regions and is being ingested with suicidal intent due to easy availability…”
Get full text

Patient‐Reported Out‐of‐Pocket Costs and Financial Toxicity During Early‐Phase Oncology Clinical Trials by Huey, Ryan W., George, Goldy C., Phillips, Penny, White, Revenda, Fu, Siqing, Janku, Filip, Karp, Daniel D., Naing, Aung, Piha‐Paul, Sarina, Subbiah, Vivek, Tsimberidou, Apostolia M., Pant, Shubham, Yap, Timothy A., Rodon, Jordi, Meric‐Bernstam, Funda, Shih, Ya‐Chen Tina, Hong, David S.

“…Background Clinical trials are an important therapeutic option for patients with cancer. Although financial burden in cancer treatment is well documented, the…”
Get full text

Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma by Perri, Giampaolo, Prakash, Laura, Qiao, Wei, Varadhachary, Gauri R., Wolff, Robert, Fogelman, David, Overman, Michael, Pant, Shubham, Javle, Milind, Koay, Eugene J., Herman, Joseph, Kim, Michael, Ikoma, Naruhiko, Tzeng, Ching-Wei, Lee, Jeffrey E., Katz, Matthew H. G.

“…OBJECTIVE:We sought to determine whether postoperative chemotherapy after preoperative therapy and pancreatectomy for pancreatic ductal adenocarcinoma (PDAC)…”
Get full text

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma by Habra, Mouhammed Amir, Stephen, Bettzy, Campbell, Matthew, Hess, Kenneth, Tapia, Coya, Xu, Mingxuan, Rodon Ahnert, Jordi, Jimenez, Camilo, Lee, Jeffrey E., Perrier, Nancy D., Boraddus, Russell R., Pant, Shubham, Subbiah, Vivek, Hong, David S., Zarifa, Abdulrazzak, Fu, Siqing, Karp, Daniel D., Meric-Bernstam, Funda, Naing, Aung

“…BackgroundAdrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. We…”
Get full text

Phase 2 study of pembrolizumab in patients with advanced rare cancers by Naing, Aung, Meric-Bernstam, Funda, Stephen, Bettzy, Karp, Daniel D, Hajjar, Joud, Rodon Ahnert, Jordi, Piha-Paul, Sarina A, Colen, Rivka R, Jimenez, Camilo, Raghav, Kanwal P, Ferrarotto, Renata, Tu, Shi-Ming, Campbell, Matthew, Wang, Linghua, Sabir, Sarjeel H, Tapia, Coya, Bernatchez, Chantale, Frumovitz, Michael, Tannir, Nizar, Ravi, Vinod, Khan, Saria, Painter, Jeane M, Abonofal, Abulrahman, Gong, Jing, Alshawa, Anas, McQuinn, Lacey M, Xu, Mingxuan, Ahmed, Sara, Subbiah, Vivek, Hong, David S, Pant, Shubham, Yap, Timothy A, Tsimberidou, Apostolia M, Dumbrava, Ecaterina E Ileana, Janku, Filip, Fu, Siqing, Simon, Richard M, Hess, Kenneth R, Varadhachary, Gauri R, Amir Habra, Mouhammed

“…Patients with advanced rare cancers have poor prognosis and few treatment options. As immunotherapy is effective across multiple cancer types, we aimed to…”
Get full text

Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial by Ngo-Huang, An T., Parker, Nathan H., Xiao, Lianchun, Schadler, Keri L., Petzel, Maria Q.B., Prakash, Laura R., Kim, Michael P., Tzeng, Ching-Wei D., Lee, Jeffrey E., Ikoma, Naruhiko, Wolff, Robert A., Javle, Milind M., Koay, Eugene J., Pant, Shubham D., Folloder, Justin P., Wang, Xuemei, Cotto, Alicia M., Ju, Ye Rang, Garg, Naveen, Wang, Huamin, Bruera, Eduardo D., Basen-Engquist, Karen M., Katz, Matthew H.G.

“…To determine the effects of a preoperative, home-based exercise program on fitness and physical function in patients with pancreatic cancer. We previously…”
Get full text

3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma by Kang, Ya'an, Deng, Jenying, Ling, Jianhua, Li, Xinqun, Chiang, Yi-Ju, Koay, Eugene J, Wang, Huamin, Burks, Jared K, Chiao, Paul J, Hurd, Mark W, Bhutani, Manoop S, Lee, Jeffrey H, Weston, Brian R, Maitra, Anirban, Ikoma, Naruhiko, Tzeng, Ching-Wei D, Lee, Jeffrey E, DePinho, Ronald A, Wolff, Robert A, Pant, Shubham, McAllister, Florencia, Katz, Matthew Hg, Fleming, Jason B, Kim, Michael P

“…BACKGROUNDPancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with unpredictable responses to chemotherapy. Approaches to assay…”
Get full text

Genetic landscape of gallbladder cancer: Global overview by Mehrotra, Ravi, Tulsyan, Sonam, Hussain, Showket, Mittal, Balraj, Singh Saluja, Sundeep, Singh, Sandeep, Tanwar, Pranay, Khan, Asiya, Javle, Milind, Hassan, Manal M., Pant, Shubham, De Aretxabala, Xabier, Sirohi, Bhawna, Rajaraman, Preetha, Kaur, Tanvir, Rath, G.K.

“…Gallbladder cancer (GBC) is a rare malignancy of biliary tract cancer (BTC), characterized by late presentation and poor prognosis. It exhibits wide…”
Get full text